Casdatifan's HIF-2α edge in ccRCC faces the Phase 3 test as domvanalimab failures narrow Arcus to a one-asset oncology story

Bull

A positive outcome would show sustained or improved ORR and PFS depth from the casdatifan plus cabozantinib cohort alongside compelling early signals from the 1L and IO-experienced cohorts, particularly the casdatifan plus zimberelimab arm where enrollment is now complete. Response rates above 40% with durable PFS in IO-experienced patients and meaningful 1L activity would validate the Phase 3 design for both PEAK-1 and the planned TKI-free study, re-rating RCUS as a credible Phase 3 asset in a high-value indication.

Bear

Disappointing outcomes would include ORR compression in the more mature dataset relative to the 45.2% signal already reported, early progression events suggesting non-durable responses, or limited activity in the 1L cohorts that raises doubts about competitive differentiation against established combination regimens. The most likely failure mode is that PFS curves flatten at longer follow-up or that the 1L zimberelimab combination does not add meaningfully over HIF-2α monotherapy, undermining the rationale for a TKI-free Phase 3.